HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karo Pharma Acquires Nordic OTCs From Teva

Executive Summary

Generics giant Teva has divested a portfolio of OTC brands marketed in the Nordics to Sweden's Karo, which has been distributing the products in the region for the past 18 months.

You may also be interested in...



EU Business Round-Up: Mayoly Spindler Acquires Biohealth, Flarin Gets Funding, Karo Ready For M&A

The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.

Teva’s Legal Woes Lead To $4.6bn Hit

Teva reported a substantial loss in the third quarter after registering a goodwill impairment of $4.6bn, largely linked to legal uncertainties as the firm continues to grapple with price-fixing litigation in the US and its pending opioids settlement.

Karo Pharma Grabs J&J’s Pevaryl Brand In Europe

Karo has picked up the full European rights to the Pevaryl antifungal brand from Johnson & Johnson.

Related Content

Topics

UsernamePublicRestriction

Register

RS150989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel